AC Immune posts positive data for Parkinson's immunotherapy [Yahoo! Finance]
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease [Yahoo! Finance]
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
AC Immune (NASDAQ:ACIU) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $8.00 price target on the stock.